<DOC>
	<DOCNO>NCT01301040</DOCNO>
	<brief_summary>The primary objective evaluate difference cardiac strain rate evolution elderly early BC patient treat ( neo ) adjuvant anthracycline-based chemotherapy compare non-anthracycline regimen ( Taxotere-cyclophosphamide ) CT . This study also compare serum biomarkers profile ( neo ) adjuvant CT treatment arm , ass whether MRI allow detect earlier standard echocardiography sign cardiotoxicity , adjuvant ( neo ) CT , ass whether brain PET-CT allow detect regional functional impairment patient receive CT , evaluate cognitive function ( neo ) adjuvant CT treatment arm , evaluate distress functional autonomy ( neo ) adjuvant CT treatment arm , evaluate psychological state burden primary caregiver ( neo ) adjuvant CT treatment arm , evaluate primary caregiver ability detect patient ' distress functional autonomy ( neo ) adjuvant CT treatment arm , evaluate short long-term toxicity profile regimen , estimate 10-year risk relapse and/or death use Adjuvant ! Online tool , estimate Framingham risk score Hard Coronary Heart Disease ( 10-year risk ) .</brief_summary>
	<brief_title>Early Cardiac Toxicity Adjuvant CT Elderly BC .</brief_title>
	<detailed_description>Considering anthracycline-based Taxotere-cyclophosphamide CT establish efficacy adjuvant treatment elderly patient early breast cancer , paucity data early cardiac toxicity anthracycline-based adjuvant therapy compare non-anthracycline regimen , first randomize study evaluate early cardiac sign base doppler myocardial imaging ( DMI ) . The result study could improve monitor cardiac function elderly patient candidate receive adjuvant chemotherapy early breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Patient selection criterion Female age equal 65 year . Histological diagnosis early BC treat physician considers ( neo ) adjuvant chemotherapy beneficial . Recommended situation : Triple negative BC pT &gt; 1cm . HER2 positive BC pT1 &gt; 1cm ; trastuzumab give study chemotherapy . `` Luminal B '' cancer define ER+ , PgR + neg , Ki67 ≥ 14 % , pT1 &gt; 1cm . `` Luminal A '' cancer ( ER+ , PgR+ Ki67 &lt; 14 % ) consider ≥ 4 node . Poor response preoperative endocrine therapy . WHO performance status equal less 1 . Baseline LVEF equal 50 % measure echocardiography . Adequate organ function include : neutrophils equal 1.5 x 109/L . platelet equal to100 x 109/L . bilirubin &lt; 1.25 x upper limit normal ( ULN ) institution . transaminase : AST &lt; 2.5 x ULN , ALT &lt; 2.5 x ULN alkaline phosphatase ≤ 2.5 x ULN institution . Estimated creatinine clearance &gt; 30ml/min ( use Crockoft Gault formula ) ( See Appendix E ) . No previous exposure chemotherapy neoadjuvant adjuvant setting . No serious cardiac illness medical condition judge investigator include , confine : Symptomatic ventricular arrhythmia , Clinical and/or ECG evidence myocardial infarction within last 12 month , Coronary artery disease require medication , Highrisk uncontrolled arrhythmia , Poorly control hypertension ( e.g . systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ) . Other concurrent serious disease may interfere plan treatment include severe pulmonary conditions/illness . No participation clinical trial involve therapeutic agent within 6 week prior randomization . No prior concurrent diagnosis cancer , except adequately treat basocellular squamous cell carcinoma skin cervical uterine situ tumor Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Signed write informed consent must give accord ICHGCP national/local regulation , prior study specific screening procedure randomization . 2 . Caregiver selection criterion identify participate patient primary caregiver i.e person help cope cancer everyday life least eighteen year old aware cancer diagnosis patient fit enough complete questionnaire French speak free cognitive dysfunction . give write informed consent regard participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>breast cancer , elderly , early cardiac toxicity</keyword>
</DOC>